论文部分内容阅读
目的评价白消安在异基因造血干细胞移植(HSCT)患者体内的药动学特征。方法 24例HSCT患者于白消安预处理第1剂前0 h与第1剂后1、2、3、4、5和6 h采集血样,利用DAS 2.0软件进行房室模型拟合,计算药动学参数,并借助SPSS20.0软件分析药动学参数的影响因素。结果第1剂静脉输注白消安后在HSCT患者体内过程符合二室模型,白消安的AUC_(0→6h)与AUC_(0→∞)分别在524.71~946.91μmol·min·L~(-1)与754.96~1 787.42μmol·min·L~(-1)范围内波动,t_(1/2α)、t_(1/2β)、CL等参数变异性大。非慢性髓细胞性白血病组与慢性髓细胞性白血病组的c_(max)之间差异有统计学意义。结论 HSCT患者体内白消安药动学参数变异性较大,有必要进行治疗药物监测。
Objective To evaluate the pharmacokinetics of busulfan in patients with allogeneic hematopoietic stem cell transplantation (HSCT). Methods Twenty-four patients with HSCT were enrolled in this study. Blood samples were taken at 0 h before and 1, 2, 3, 4, 5 and 6 h after the first dose of busulfan pretreatment. DAS 2.0 software was used to fit atrioventricular model, Kinematics parameters, and analysis of pharmacokinetic parameters using SPSS20.0 software. Results The first intravenous infusion of busulfan in HSCT patients with two-compartment model of the process, the busulfan AUC_ (0 → 6h) and AUC_ (0 → ∞) were 524.71 ~ 946.91μmol · min · L ~ ( -1) and 754.96-1787.42μmol · min · L -1, the variability of t 1 / 2α, t 1 / 2β, CL and other parameters were large. There was a significant difference between c_ (max) and non-chronic myelogenous leukemia group and chronic myeloid leukemia group. Conclusion The pharmacokinetic parameters of busulfan in HSCT patients are quite variable, so it is necessary to monitor the therapeutic drugs.